Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Rhonda Chanson

Internal Medicine Charleston, SC Medical Doctor

NPI 1609828706 CMS profile 208407

2270 Ashley Crossing Dr Ste 135, Charleston, SC 29414

Open in the dashboard

General payments

$3,354

203 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Rhonda Chanson of Charleston, SC is reported in the CMS Open Payments database as having received $3,354 across 203 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $554 30
2022 General $606 35
2021 General $926 57
2020 General $735 47
2019 General $533 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rhonda Chanson
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Rhonda Chanson were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Rhonda Chanson Internal Medicine median Middle half National median
2019 $533 $159 $48–$570 $163
2020 $735 $119 $33–$402 $114
2021 $926 $135 $37–$521 $132
2022 $606 $141 $42–$496 $149
2023 $554 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Lilly USA, LLC $417 26 payments
  2. AbbVie, Inc. $355 23 payments
  3. Novo Nordisk Inc $288 19 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $253 15 payments
  5. Astellas Pharma US Inc $200 10 payments
  6. Pfizer Inc. $200 11 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $199 12 payments
  8. GlaxoSmithKline, LLC. $158 9 payments
  9. AstraZeneca Pharmaceuticals LP $137 10 payments
  10. Novartis Pharmaceuticals Corporation $136 8 payments
  11. Other $1,012 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,339 201 payments
  2. Education $15 2 payments
Products named General payments · program years 2019–2023
  1. JARDIANCE Diabetes $319 20 payments
  2. TRULICITY $297 19 payments
  3. JARDIANCE Diabetes $238 13 payments
  4. Ozempic $186 13 payments
  5. UBRELVY $183 12 payments
  6. MYRBETRIQ $182 9 payments
  7. XIFAXAN $181 11 payments
  8. RYBELSUS $162 11 payments
  9. GLYXAMBI $146 8 payments
  10. ENTRESTO $136 8 payments
  11. Other $3,018 187 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

422

Median for Internal Medicine: 777

Drug cost

$6,402

Median for Internal Medicine: $73,373

Branded share of claims

2.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rosuvastatin Calcium Generic 66 $1,148
Atorvastatin Calcium Generic 54 $924
Levothyroxine Sodium Generic 52 $618
Synthroid Levothyroxine Sodium Brand 12 $610
Valsartan Generic 19 $451
Amlodipine Besylate Generic 61 $432
Losartan Potassium Generic 22 $415
Potassium Chloride Generic 12 $401
Omeprazole Generic 16 $334
Simvastatin Generic 18 $260

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

203 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record